RxDoctor Payments Data

Emily Gantt

Adult Health · Shelby, NCNPI 1285627612

Payments from drug & device makers

$768in general payments, 2019–2025

Across 49 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$197
  • Johnson & Johnson$149
  • AstraZeneca$136
  • AbbVie$84
  • GSK$48
  • Pfizer$36
  • plus $117 from 6 others

What the payments were for

  • Food & beverage$768100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$768 in reported general payments places this provider in the 60th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$201,158
Medicare patients
236
Services billed
6,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter139$108,389
EliquisApixaban109$95,572
FarxigaDapagliflozin Propanediol107$83,060
OzempicSemaglutide51$65,569
Breo ElliptaFluticasone/Vilanterol98$43,154
RybelsusSemaglutide39$39,721
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$31,382
MounjaroTirzepatide28$30,884
Tresiba Flextouch U-100Insulin Degludec24$25,130
JanuviaSitagliptin Phosphate12$16,277
XareltoRivaroxaban21$16,122
Spiriva RespimatTiotropium Bromide22$11,040
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$5,211
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$4,843
Incruse ElliptaUmeclidinium Bromide11$4,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$48$157,932260 claims
AstraZenecaFarxiga, Breztri Aerosphere$136$114,441141 claims
Novo NordiskOzempic, Rybelsus$197$105,29090 claims
PfizerEliquis$36$95,572109 claims
Johnson & JohnsonXarelto$149$16,12221 claims
Boehringer IngelheimSpiriva Respimat$16$11,04022 claims
AbbVieSynthroid$84$2,62035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 614 adult health providers in North Carolina.

Other adult health in Shelby

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →